super cool life

Chapter 177 Poor, sad, deplorable, hateful
In Guo Yongren's mind, he couldn't help but come up with the information he found by accident when searching the Internet. The history of blood and tears in the development of Chinese traditional medicine is completely a tragedy, pitiful, sad, deplorable, and hateful.

According to statistics in 2014, the global Chinese medicine market was about 2014 billion in 1000, while my country only accounted for 9%. This data comes from the statistics of a foreign company.There may be a bias, but not too much.It is generally accepted in the industry that foreign companies such as South Korea, Japan, and the United States have directly monopolized about 90% of the international market for Chinese patent medicines.

According to statistics, in the overseas Chinese medicine market, China has only 0.3% of patent rights, while Japan and South Korea account for more than 70% of Chinese medicine patents.

Tsumura Pharmaceuticals, Japan's largest Kampo pharmaceutical company, has successively established more than 70 GAP medicinal material planting bases in my country, while Tong Ren Tang, the traditional Chinese medicine company with the most GAP bases in my country, has only 8, and there is a huge gap in quantity.

截至2014年5月底，我国已认证通过66个中药材品种共152个GAP种植基地，其中70多个GAP药材种植基地被日本-津村药业管控，不知道剩余的80左右的GAP药材种植基地还有多少被日本或其他国家掌控。

GAP refers to the "Quality Management Regulations for the Production of Chinese Medicinal Materials", which stipulates that research and development, production and management are carried out in accordance with internationally recognized standards.

In addition to the medicinal materials produced by the GAP medicinal planting base in Japan, which are exported to Japan, a large number of high-quality raw materials of Chinese medicinal materials that do not exceed the standard of heavy metals, pesticides and that are not vulcanized are also exported to Japan in large quantities.

At the same time, Japanese pharmaceutical companies strictly control the quality of traditional Chinese medicine raw materials, and resolutely do not allow heavy metals, pesticides, or other unqualified Chinese medicinal materials to enter their production workshops.

It is a terrifying thing that a Japanese pharmaceutical company controls nearly half of the GAP medicinal material planting base in China.

Japan's strategy in Chinese medicine is a clear "prescriptions originate from China, and medicinal materials come from China. When Chinese Chinese medicine companies are still self-indulgent, they will close the door to the internationalization of Chinese medicine and maximize their share in the international Chinese medicine market. .”

Because Japanese pharmaceutical companies understand that the origin of traditional Chinese medicine is China, but Chinese traditional Chinese medicine does not have global competitiveness, Japanese pharmaceutical companies rushed to register some patents of famous Chinese traditional medicine prescriptions in the European and American markets.For example, Japan’s Imperial Pharmaceutical Co., Ltd. preemptively registered U.S. patents for proprietary medicines such as Jiawei Xiaoyao San, Danggui Shaoyao Decoction, Guizhi Fuling Pills, and ulcerative colitis medicines.

Due to the existence of patents, European and American pharmaceutical companies with strong intellectual property rights cannot produce, and at the same time, Chinese pharmaceutical companies in the place of origin are also unable to produce. Japanese pharmaceutical companies have really clever management methods.

These pieces of information slowly surfaced in Guo Yongren's mind. This can be said to be the pain in the hearts of all Chinese people, but since he came here, then these must be taken back. The monopoly of traditional Chinese medicine must belong to the umbrella. It had to be discussed, Guo Yongren made up his mind.

"How about Naomi, I'm going to Tokyo tomorrow too, let's go together" Guo Yongren said directly, Naomi Hosokawa had no doubt about him, and nodded in agreement.

The next day, Guo Yongren returned to Tokyo with Guan Du, Wang Dajun, and Hosokawa Naomi. Nagoya was handed over to Takahashi Shogo. There were not many things, and Takahashi Shogo and the others had no problems at all.

When they arrived in Tokyo, Guo Yongren and Hosokawa Naomi separated. When Guo Yongren returned to the hotel, he went to Guandu directly, and asked Guandu to find out the foundation of the Ono Chinese medicine company that declared bankruptcy, and at the same time learn about the current situation of Japanese Chinese medicine companies. What is the status quo like? I gave Guan Du a check and let Guan Du go to work.

It’s easy to do things with money, the principle is the same everywhere, spent 10,000+ US dollars, a week’s time, a detailed report was placed in front of Guo Yongren, Guo Yongren watched carefully, life is not easy for Japanese Chinese medicine companies in this year , It can be said that they are struggling to get by. There are many companies that cannot publish new books, and many small businesses have gone bankrupt. This is a good time to buy the bottom.

The information is very detailed. These companies have their own unique products. Guo Yongren thought for a while and called Guan Du over, and the two began to discuss in the room.

Pass the enterprise directory to Guan Du, "Those circled on it, all will be acquired." Guo Yongren said directly, not considering other things at all, let's take it first, not to mention that the acquisition cost is not high now.

Guan Du took a look. There are more than a dozen companies, all of which are pharmaceutical factories. The scale is not large, and the life of the companies is not easy. Why buy a pharmaceutical company, and it is still traditional Chinese medicine. Now people take western medicine when they are sick. , It works quickly, and it also cures diseases, which is of no value. I looked at Guo Yongren a little puzzled.

"Don't ask why, let's do it, take this, the sooner the better" Guo Yongren said directly, not in the mood to explain now, and at the same time gave Guan Du a cash check of 50 US dollars as the activity fund, Guan Du nodded, Guo Yongren is the boss, and the boss can do it himself if he has a decision.

He took the catalog and went out, and began to investigate more detailed information for negotiation. The boss, of course, the sooner the better, then there must be enough information, and he entrusted several well-known private investigators to start the operation.

Guan Du now goes out early and returns late every day. Guo Yongren basically stays in the hotel and does not have a mobile phone. It is very inconvenient to contact, so he does not go there, and keeps in touch with Guan Du at any time.

It took only ten days to complete the first company, followed by one company every day, and within a month, all the companies on Guo Yongren's list were acquired.

Immediately afterwards, Guo Yongren did not start to integrate, but immediately began to apply for patents for the formulas and names of traditional Chinese medicine products held by these companies. He was not afraid of spending money. A patent would cost a lot of money, but the money must be spent. Guo Yongren I don't care, Guan Du is as tired as a donkey during this period, and the eyes he looks at Guo Yongren every day are full of deep resentment.

After all the patent material applications were submitted, Guo Yongren and Guan Du breathed a sigh of relief, especially Guo Yongren, in order to ensure a smooth implementation, specially spent money to hire a lobbying company. Japan was established after the United States, and the price was not cheap. 80 US dollars to ensure the smooth approval of the patent, Guo Yongren paid directly and signed an agreement without saying a word, and let this Japanese lobbying company operate.

After all these things were done, Guo Yongren started to integrate these dozens of Chinese medicine companies, and began to take stock of all assets. After the stocktaking, Guo Yongren smiled. This time the acquisition only cost more than 3000 million US dollars, and we can see the harvest. At that time, Guo Yongren felt that he was really lucky.

More than a dozen companies have eight ready-made buildings in Tokyo, the highest is [-] floors, the lowest is [-] floors, and there are also assets such as factories in the suburbs. You must know that it is only [-], and Tokyo is one of the cities with the highest housing prices in the world. One, how much these will appreciate in the future is simply unimaginable.

Another thing that makes Guo Yongren very gratified is that these dozens of companies are basically managed by families. After Guo Yongren acquired them, many high-level executives left consciously. These people do not have much ability, but they occupy high positions. , It's all right now, a lot of seats have been vacated.

Guo Yongren started another round of intense interviews. At the same time, he looked through their resumes. It took a whole week to determine the candidates for the umbrella medical department. There are quite a few people.

The [-]-storey building with a good location was officially renamed the Umbrella Medical Building and started new renovations. It will be the headquarters of the Japanese pharmaceutical company.

Hidesuke Yoda: Appointed as General Manager of Umbrella Pharmaceuticals (Japan Branch)

Hideyuki Tanaka: Appointed as Deputy General Manager of Umbrella Pharmaceuticals (Japan Division)

Kamiji Ida: Appointed as Deputy General Manager of Umbrella Pharmaceuticals (Japan Division)

Kaede Hasegawa: Appointed as Manager of Administration Department of Umbrella Pharmaceuticals (Japan Division)
Keshou Hokumi: Appointed as the manager of the medicinal material procurement department of Umbrella Pharmaceuticals (Japan Branch)
Yuji Ohno: Appointed as deputy manager of the medicinal materials procurement department of Umbrella Pharmaceuticals (Japan Branch)

Mitsui Yan Hui: Appointed as Deputy Manager of the Purchasing Department of Umbrella Pharmaceuticals (Japan Branch)

Professor Tomoko Saihei: Appointed as Director of Research Department of Umbrella Pharmaceuticals (Japan Branch)
Professor Mu Muchenhachi: Appointed as Minister of Science and Technology of Umbrella Pharmaceutical Company (Japan Branch)

Professor Hidechu Sato: Appointed as Minister of Science and Technology of Umbrella Pharmaceuticals (Japan Branch)
Shuichi Minamino: Appointed as Sales Director of Umbrella Pharmaceuticals (Japan Division)

Ryui Miyazaki: Appointed as Deputy Director of the Sales Department of Umbrella Pharmaceuticals (Japan Branch)

Kiyoshi Kobayashi: Appointed as Deputy Director of the Sales Department of Umbrella Pharmaceuticals (Japan Branch)

Toshihiko Nakajima: Appointed as Director of Quality Control Department of Umbrella Pharmaceuticals (Japan Division)
Yuehuaren: Appointed as Deputy Director of Quality Control Department of Umbrella Pharmaceutical Company (Japan Branch)
Hanazawa Takuya: Appointed as Deputy Director of Quality Control Department of Umbrella Pharmaceutical Company (Japan Branch)

Ryuichi Horibe: Appointed as Deputy Director of the Quality Control Department of Umbrella Pharmaceuticals (Japan Branch)

Katsuhei Yamaguchi: Appointed as Marketing Manager of Umbrella Pharmaceuticals (Japan Division)
Kazuhiko Inoue: Appointed as Deputy Manager of the Marketing Department of Umbrella Pharmaceuticals (Japan Division)

Nagato Takashi: Appointed as Deputy Manager of the Marketing Department of Umbrella Pharmaceuticals (Japan Branch)

It is not difficult to see from this appointment that Guo Yongren has put a lot of effort into product quality control. The other departments are basically equipped with one official and two copies, but the quality control department is equipped with one official and three copies. Product quality is the survival of the company. No matter how hard you work, you can't overdo it.

At the same time, Guo Yongren transferred two accountants from Hong Kong to form the Finance Department of Umbrella Pharmaceutical Company. The international accounting firm PricewaterhouseCoopers acted as the company’s contracted audit agency, and the Japanese branch of the American Fearson Law Firm served as the legal audit agency of the pharmaceutical company. All contracts that have not been signed and confirmed by the Legal Review Department are illegal contracts.

　Today's three updates are all big chapters, thank you for your support! ! ! ! !

　　
　
(End of this chapter)